Taken together, the combination of gefitinib and elemene exhibits the remarkably enhanced anti-cancer activity, with potential to overcome EGFR-TKI resistance, to inhibit cancer stemness and to repress cancer development capability in xenograft mice. Here, EGFR is linked to cancer.